scPharmaceuticals (SCPH) Competitors

LENZ Therapeutics (NASDAQ:LENZ) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.

Does the media prefer LENZ or SCPH?

In the previous week, LENZ Therapeutics had 3 more articles in the media than scPharmaceuticals. MarketBeat recorded 5 mentions for LENZ Therapeutics and 2 mentions for scPharmaceuticals. scPharmaceuticals' average media sentiment score of 1.22 beat LENZ Therapeutics' score of 1.10 indicating that scPharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
scPharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is LENZ or SCPH more profitable?

LENZ Therapeutics has a net margin of 0.00% compared to scPharmaceuticals' net margin of -264.60%. LENZ Therapeutics' return on equity of -58.48% beat scPharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-58.48%	-55.50%
scPharmaceuticals	-264.60%	-244.93%	-68.56%

Does the MarketBeat Community favor LENZ or SCPH?

scPharmaceuticals received 148 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 67.08% of users gave scPharmaceuticals an outperform vote.

Company	Underperform	Outperform
LENZ Therapeutics	Outperform Votes 15 100.00%	Underperform Votes No Votes
scPharmaceuticals	Outperform Votes 163 67.08%	Underperform Votes 80 32.92%

Which has more risk & volatility, LENZ or SCPH?

LENZ Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.

Do analysts recommend LENZ or SCPH?

LENZ Therapeutics presently has a consensus target price of $46.60, indicating a potential upside of 57.54%. scPharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 250.00%. Given scPharmaceuticals' higher probable upside, analysts clearly believe scPharmaceuticals is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
scPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals have more ownership in LENZ or SCPH?

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by company insiders. Comparatively, 4.8% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings & valuation, LENZ or SCPH?

scPharmaceuticals has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	N/A	N/A	-$124.65M	-$1.77	-16.71
scPharmaceuticals	$41.98M	5.03	-$54.81M	-$1.91	-2.09

Summary

LENZ Therapeutics beats scPharmaceuticals on 11 of the 18 factors compared between the two stocks.